Deals Of The Week: BioCryst/Presidio, Merck/AiCuris, Kite/National Cancer Institute
Executive Summary
The termination of a Phase III trial for Abbott/Reata’s projected blockbuster bardoxolone is just one of several recent major blow-ups of a significant pharma/biotech collaboration. One analyst thinks narrow, short-term thinking by business development execs links all of the clinical letdowns.